The Pharmasyntez Group is the title partner of the 24th Pharmacy Summit, one of the most significant and large-scale events in the pharmacy market. Nikita Punia, the company’s Executive Director, spoke at the "Kings of the Hill, or News from the Pharmacy Olympus" plenary panel of market leaders:

"We are actively expanding our presence in the Russian hormonal drug market, having invested over 5 billion rubles in the unique Pharmasyntez-Tyumen production facility, which has allowed us to capture 5% of the market in just two years," Nikita Punia noted. Additionally, he stated that import substitution has a great deal of potential and that imported drugs make up 95% of the market.

With an emphasis on consumer accessibility to medications, the company is actively collaborating with the retail sector and intends to grow its footprint. Punia underlined that in order to guarantee successful implementation and customer trust, Russian retail should promote the availability and dependability of domestic medications, particularly in the area of hormonal medications. Successfully promoting Russian products in the market requires striking a balance between the interests of consumers and pharmacy chains.

The Pharmasyntez Group holds a leading position in the public procurement sector and is actively expanding its presence in the retail pharmacy network. In this regard, the company’s strategy is focused on developing technologically complex drug production, increasing its presence in a variety of therapeutic segments, and substituting imports.

Pharmasyntez sees numerous product niches in which it can expand and fortify its position. This suggests opportunities for additional growth in the retail and public sectors.

Drug accessibility has a direct impact on market volumes and demand. Pharmacy chains will use the product once demand is established, according to the market economy. Creating consumer demand for reasonably priced medications is a crucial success factor. New models of market participant interaction must be developed in order to guarantee drug accessibility while preserving economic efficiency for all parties.The Pharmasyntez Group is the title partner of the 24th Pharmacy Summit, one of the most significant and large-scale events in the pharmacy market. Nikita Punia, the company’s Executive Director, spoke at the "Kings of the Hill, or News from the Pharmacy Olympus" plenary panel of market leaders:

"We are actively expanding our presence in the Russian hormonal drug market, having invested over 5 billion rubles in the unique Pharmasyntez-Tyumen production facility, which has allowed us to capture 5% of the market in just two years," Nikita Punia noted. Additionally, he stated that import substitution has a great deal of potential and that imported drugs make up 95% of the market.

With an emphasis on consumer accessibility to medications, the company is actively collaborating with the retail sector and intends to grow its footprint. Punia underlined that in order to guarantee successful implementation and customer trust, Russian retail should promote the availability and dependability of domestic medications, particularly in the area of hormonal medications. Successfully promoting Russian products in the market requires striking a balance between the interests of consumers and pharmacy chains.

The Pharmasyntez Group holds a leading position in the public procurement sector and is actively expanding its presence in the retail pharmacy network. In this regard, the company’s strategy is focused on developing technologically complex drug production, increasing its presence in a variety of therapeutic segments, and substituting imports.

Pharmasyntez sees numerous product niches in which it can expand and fortify its position. This suggests opportunities for additional growth in the retail and public sectors.

Drug accessibility has a direct impact on market volumes and demand. Pharmacy chains will use the product once demand is established, according to the market economy. Creating consumer demand for reasonably priced medications is a crucial success factor. New models of market participant interaction must be developed in order to guarantee drug accessibility while preserving economic efficiency for all parties.